Clinical Cancer Research, Vol 1, Issue 12 1595-1601, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin

ID Kurzman, EG MacEwen, RC Rosenthal, LE Fox, ET Keller, SC Helfand, DM Vail, RR Dubielzig, BR Madewell and CO Rodriguez Jr
School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin 53706, USA.

Two randomized, double-blind clinical trials in dogs with spontaneous appendicular osteosarcoma treated with combination chemoimmunotherapy are reported. In both trials, dogs without overt metastasis underwent complete amputation of the affected limb. In trial 1, 40 dogs were treated with cisplatin chemotherapy [(CDDP), 70 mg/m2 i.v. every 28 days x 4]. Following CDDP, dogs without evidence of overt metastasis (n = 25) were randomized to receive liposome-encapsulated muramyl tripeptide phosphatidylethanolamine ](L-MTP-PE), 2 mg/m2 i.v.) or placebo liposomes (lipid equivalent) twice weekly for 8 weeks. Of 14 dogs in the placebo group, 13 (93%) died of metastasis; the median survival time was 9.8 months. Of 11 dogs in the L-MTP-PE group, 8 (73%) developed metastasis; the median survival time was 14.4 months, which was significantly longer than that of the placebo group (P < 0.01). In trial 2, 64 dogs received CDDP (70 mg/m2 i.v. every 21 days x 4) and were randomized to concurrently receive L-MTP-PE (2 mg/m2 i.v.) twice or once weekly, or placebo liposomes once weekly for 8 weeks. Median survival times were 10.3, 10.5, and 7.6 months, respectively. There were no significant differences among the three treatment groups in trial 2. Survival times for dogs receiving L-MTP-PE in trial 1 were significantly longer than those for dogs in trial 2 that received four doses of CDDP concurrently with twice weekly L-MTP-PE (P < 0. 04). The results of the first trial confirm our previous observation that L-MTP-PE has antimetastatic activity in dogs with osteosarcoma when given following amputation. The results of the second trial demonstrate that there is no survival advantage of administering L-MTP-PE concurrently with CDDP.

This article has been cited by other articles:

				L. M. Jeys, R. J. Grimer, S. R. Carter, R. M Tillman, and A. Abudu Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated? Ann. Surg. Oncol., October 1, 2007; 14(10): 2887 - 2895. [Abstract] [Full Text] [PDF]

				B. D. X. Lascelles, W. S. Dernell, M. T. Correa, M. Lafferty, C. M. Devitt, C. A. Kuntz, R. C. Straw, and S. J. Withrow Improved Survival Associated With Postoperative Wound Infection in Dogs Treated With Limb-Salvage Surgery for Osteosarcoma Ann. Surg. Oncol., December 1, 2005; 12(12): 1073 - 1083. [Abstract] [Full Text] [PDF]

				R. Chun, L. D. Garrett, C. Henry, M. Wall, A. Smith, and N. M. Azene Toxicity and Efficacy of Cisplatin and Doxorubicin Combination Chemotherapy for the Treatment of Canine Osteosarcoma J. Am. Anim. Hosp. Assoc., November 1, 2005; 41(6): 382 - 387. [Abstract] [Full Text] [PDF]

				D. M. Cooley, B. C. Beranek, D. L. Schlittler, N. W. Glickman, L. T. Glickman, and D. J. Waters Endogenous Gonadal Hormone Exposure and Bone Sarcoma Risk Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1434 - 1440. [Abstract] [Full Text] [PDF]

				E. G. MacEwen, I. D. Kurzman, D. M. Vail, R. R. Dubielzig, K. Everlith, B. R. Madewell, C. O. Rodriguez Jr., B. Phillips, C. H. Zwahlen, J. Obradovich, et al. Adjuvant Therapy for Melanoma in Dogs: Results of Randomized Clinical Trials Using Surgery, Liposome-encapsulated Muramyl Tripeptide, and Granulocyte Macrophage Colony-stimulating Factor Clin. Cancer Res., December 1, 1999; 5(12): 4249 - 4258. [Abstract] [Full Text] [PDF]

				S. Visonneau, A. Cesano, K. A. Jeglum, and D. Santoli Adjuvant Treatment of Canine Osteosarcoma with the Human Cytotoxic T-Cell Line TALL-104 Clin. Cancer Res., July 1, 1999; 5(7): 1868 - 1875. [Abstract] [Full Text] [PDF]